US3390050A - Stable pharmaceutical beads conaining medicament incorporated in synthetic copolymerby bead polymerization - Google Patents

Stable pharmaceutical beads conaining medicament incorporated in synthetic copolymerby bead polymerization Download PDF

Info

Publication number
US3390050A
US3390050A US462450A US46245065A US3390050A US 3390050 A US3390050 A US 3390050A US 462450 A US462450 A US 462450A US 46245065 A US46245065 A US 46245065A US 3390050 A US3390050 A US 3390050A
Authority
US
United States
Prior art keywords
acid
grams
synthetic
release
copolymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US462450A
Inventor
Speiser Peter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BASF Corp
Novartis Corp
Original Assignee
Ciba Geigy Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Corp filed Critical Ciba Geigy Corp
Application granted granted Critical
Publication of US3390050A publication Critical patent/US3390050A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2/00—Processes of polymerisation
    • C08F2/44—Polymerisation in the presence of compounding ingredients, e.g. plasticisers, dyestuffs, fillers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Definitions

  • the present invention relates to pharmaceutical preparations in head form, especially for oral administration, which contain the active ingredient, or mixture of active ingredients, incorporated in physiologically acceptable synthetic polymers, that can be dissolved or swollen by the stomach juice and/or intestinal juice, and to the manufacture of such pharmaceutical preparations.
  • solid pharmaceutical preparations for example, for oral administration, were made by aggregating the active ingredient, either alone or in admixture with known adjuvants, for example, starch, sugar, talc, flavouring agents, and the like, and compressing the aggregate into flat circular discs of varying porosity on a tablet compressing machine.
  • adjuvants for example, starch, sugar, talc, flavouring agents, and the like.
  • Preparations in this form are a further development of the powder which constitutes a single dose. They have many advantages over powders in that they permit more exact dosage, are easier for the patient to take, and permit more accurate selection of the region where resorption is to take place, for example, the mucous membranes of the mouth or of the gastro-intestinal tract.
  • tablets have a longer storage lifebecause they present a small surface area to the hostile environment than powders.
  • a feature which both tablets and powders have in common is that they release the medicament quickly.
  • the purpose of these tablets is to release the active ingredient, either with or without an initial dose, over a period of several hours, the release being effected either continuously or in portions, the object being to keep the level of active ingredient in the blood as constant as possible.
  • the medicament is coated with a material which is resistant to the acid secretion of the stomach but which 'is soluble in the secretion of the small intestine, thus preventing quick and premature release in the stomach.
  • the materials first used for such coatings were natural products such as fats and waxes, and these were followed by synthetic adjuvants, which were mainly acrylic and cellulose derivatives.
  • the medicaments are mixed with syntheic materials of an appropriate grain size which are inert towards and insoluble in the intestinal juice, for example, polyvinyl chloride or polystyrene, and the mixture is compressed into tablets by a known method. The soluble medicament slowly diffuses out of this porous housing.
  • the pharmaceutical preparations of the invention have substantial technical and pharmacological advantages over the preparations known hitherto. They have a smooth surface which may be transparent or opaque and can be attractively coloured as required. Their manufacture is simple in comparison with other products, especially injection-moulded tablets, since expensive apparatus is not required. They are suitable for both small-scale and large-scale production. Furthermore, the size of the beads can be controlled in a very simple manner, which means that the release of the active ingredient can also be precisely controlled in respect of both amount and time. It has also been found that, in many cases, active ingredients incorporated in such preparations are more stable because the material with which they are coated or in which they are embedded is protective and mechanically stable. They also show a high degree of resistance to atmospheric influence. Since they generally exhibit a low degree of permeability to water, the preparations made by the process of the invention are special-1y suitable for hygroscopic medicaments and/ or medicaments that are sensitive to moisture.
  • the preparations made by the process of the invention may be used per se, for example, in the form of granules, if desired, in capsules, or suspended in a liquid, for example, as a suspension or in the form of a syrup.
  • the product may also be admixed with adjuvants, and compressed into tablets in the customary manner.
  • the synthetic materials used are those whose monomers can be subjected to bead polymerization in the presence of the active ingredients and which, when cured, yield a physiologically acceptable polymer of adequate strength that can be at least swollen, e.g. dissolved by the gastrointestinal juices.
  • Synthetic materials of the kind defined are advantageously copolymers of methacrylic acid and methylmethacrylate, acrylic acid and acrylic acid methyl ester, vinyl acetate and crotonic acid, styrene and acrylic acid, and/or maleic anhydride, vinyl methyl ether and maleic acid anhydride and/or fumaric acid and/or itaconic acid, and the swelling capacity and alkali-solubility of the synthetic material can be regulated by changing the proportion of free acid present in the copolymer.
  • the ratio of active ingredient to synthetic material in the preparations of the invention depends on the dosage of active ingredient and the desired rate of release.
  • the new preparations may also contain fillers or swelling agents, for example, parafiins, starch derivatives, talc, stearates, and also electrolytes.
  • interfaceactive substances such as fatty alcohols or fatty acids may be added to render lipophilic substances hydrophilic, and substances which render hydrophilic substances lipophilic, such as alkylamines, for example, hexadecylamine, or organic silicones, for example, dirnethyldichlorosilane.
  • They may also contain the medicament, or mixture of medicaments, or parts thereof, enveloped in wax or fat, and also synthetic resins that are insoluble in the stomach juice and/or intestinal juice and that are not swollen thereby, and thus constitute a prolonged release preparation.
  • the new pharmaceutical preparations of the invention are obtained when a medicament, or a mixture of medicaments, if desired or required, together with fillers and swelling agents and/or further adjuvants, is subjected to bead polymerization in admixture with monomers which yield physiologically acceptable synthetic materials which are dissolved or swollen by the stomach juice and/ or intestinal juice when polymerized.
  • the medicament or mixture of medicaments may be dissolved or suspended in the monomers, the adjuvants added, and
  • the mixture thus obtained dispersed, for example, by stirring, in a dispersing agent with which it is immiscible, for example, water, in such a manner that beads having the requisite degree of fineness are obtained.
  • a dispersing agent with which it is immiscible, for example, water
  • Polymerization may even be carried out at room temperature if the appropriate monomers are used, although it is normally carried out at an elevated temperature.
  • the beads that are formed are separated from the dispersing agent, washed, and dried.
  • the catalyst used is one of those normally employed for this reaction, for example, an inorganic or organic peroxide, for example, benzoyl peroxide and tertiarybutyl hydroperoxide or an azonitrile, for example, Ot-aZO- diiso-outyronitrile.
  • an organic tertiary-amine, an iron salt, manganese, cobalt, a sulphinic acid or a sulphite can be added to accelerate polymerization.
  • Example 1 10 grams of -(l-cyclohexenyl)-5-ethyl-calcium barbiturate and 32 grams of a vinyl acetate-crotonic acid copolymer (92:8) are dissolved in a mixture of 40 grams of methacrylic acid monomer and 25 grams of methylmethacrylate monomer.
  • the viscous solution is emulsified in 200 millilitres of a solution of 0.4 gram of sodium polyacrylate and 20 grams of sodium sulphate in 100 millilitres of water in a vessel provided with stirring means, a reflux condenser and a tube for the introduction of gas; 0.5 millilitre of benzoyl peroxide is added, and the batch is polymerized at about 60 C.
  • the product consists of dull white beads between 0.1 and 3.0 millimetres in diameter and having a smooth surface.
  • the beads are washed with distilled water and, if desired, dried at 40 C.
  • Example 2 grams of acctyl-para-phenetidine and 30 grams of a copolymer from acrylic acid ethyl ester, tertiary butylacrylamide and acrylic acid are dissolved or suspended in a mixture comprising 40 grams of methacrylic acid monomer and 27 grams of methylmethacrylate monomer.
  • the suspension is further treated and polymerized in a manner analogous to that described in Example 1, but at a temperature of 50 C. and a stirring speed of 500 r.p.m. Polymerization is finished after about 2 hours, the product comprising yellowish white beads having a mean diameter of 0.2 to 0.3 millimetre.
  • Example 3 100 grams of 2-etl1yl-2-phenyl-glutarimide are dissolved in a solution of 30 grams of a vinyl acetate-crotonic acid copolymer (92:8) in 40 grams of methacrylic acid monomer and 30 grams of methyl-methacrylate monomer.
  • solution is emulsified in 550 millilitres of a solution of 0.4
  • Example 4 grams of papaverine base and 20 grams of a vinyl acetate-crotonic acid copolymer (92:8) are dissolved in 43 grams of methyl-methacrylate monomer.
  • the solution is emulsified in 275 millilitres of a solution of 0.4 gram of sodium polyacrylate and 20 grams of sodium sulphate in 100 millilitres of water in a manner analogous to that described in Example 1.
  • 0.3 millilitre of benzoyl peroxide is added, and the batch is polymerized at 50 C. at a stirring speed of 200 r.p.m. After 1 hour, greenish brown beads having a mean diameter of l to 3 millimetres are obtained.
  • Example 5 15 grams of arachis oil, 15 grams of a copolymer from acrylic acid ethyl ester, tertiary butylacrylamide and acrylic acid and 20 grams of 4-dimethylamino-l-phenyl-Z:3- dimethylpyrazolone-S are trituratcd With grams of methylmethacrylate, and then further treated and polymerized in a manner analogous to that described in Example 1, but at a stirring speed of 500 r.p.m. Yellowish white beads having a mean diameter of 0.2 to 0.4 millimetre are obtained.
  • Example 6 10 grams of hydrocortisone are suspended in 90 grams of a mixture comprising 3 grams of methylmethacrylate, 3 grams of polyvinyl acetate-crotonic acid copolymer (92:8) and 4 grams of methacrylic acid. 0.5 millilitre of benzoyl peroxide is added and the suspension is emulsified in 250 millilitres of a solution comprising 0.4 gram of sodium polyacrylate and 20 grams of sodium sulphate per 100 millilitres of water. The batch is then polymerized for 3 hours at C. while stirring at 250 r.p.m. and with the introduction of CO White beads having a mean diameter of 0.7 to 2.0 millimetres are obtained.
  • Example 7 25 grams of N-[6-methoxy 2 (methoxymethyl)-4- pyrimidinyl]-sulphanilimide are dissolved at C. in grams of a mixture comprising 3 grams of polyvinyl acetate-crotonic acid copolymer (92:8), 3 grams of methylmethacrylate and 4 grams of methacrylic acid. 0.07 gram of a-azoisobutyronitrile is added and the mixture is then emulisfied in 250 millilitres of a solution of 0.4 gram of sodium polyacrylate and 20 grams of sodium sulphate in 100 millilitres of water. The batch is polymerized for 2 hours at 70 C. while stirring at 300 r.p.m. and with the introduction of CO Yellow translucent beads having a mean diameter of 0.5 to 1.0 millimetre are obtained.
  • Example 8 15 grams of 3-acetylamino-2z4:6-tri-i0dobenz0ic acid (Acetrizons DCI) in the form of the sodium salt are dissolved at 70 C. in grams of a mixture comprising 3 grams of methylmethacrylate, 3 grams of polyvinyl acetate-crotonic acid copolymer (92:8) and 4 grams of methacrylic acid. 0.2 gram of benzoyl peroxide is added and the mixture is then emulsified in 250 millilitres of a solution of 0.3 gram of high-molecular polyethylene glycol and 10 grams of sodium suphate in millilitres of dilute hydrochloric acid (0.01 N). The batch is polymerized for 3 hours at 70 C. while stirring at 250 r.p.m. and with the introduction of CO White beads having a mean diameter of 0.5 to 1.0 millimetre are obtained.
  • Example 9 20 grams of N [6-methoxy 2 (methoxymethyl)-4- pyrimidinyl]-sulphamilamide are dissolved at 70 C. in 80 grams of a mixture comprising 10% of methacrylic acid, 40% of methyl methacrylate, 30% of polyvinyl acetate crotonic acid coploymer (92:8) and 20% of divinylbenzene. After dispersion in 300 ml. of a saturated aqueous solution of sodium sulfate with 0.4% of polyacrylate having a pH value of 6, the batch is copolymerised with the addition of 0.2 gram of azoisobutyronitrile at 70 C. for 5 hours at a stirring rate of 300 rotations per minute.
  • the resulting beads show a half value period for the release of active substance of one hour in artificial intestinal juice having a pH value of 7.5 at 37 C.
  • Example 10 20 grams of N-[6-methoxy 2 (methoxymethyl)-4- pyrimidinyl]-sulphamilamide are processed with 80 grams of a mixture of 50% of methacrylic acid, 30% ot a copolymer of polyvinyl acetate-l-crotonic acid (92:8) and 20% of divinylbcnzene under the same conditions as described in Example 9 to form beads.
  • the resulting beads show a half value period for the release in artificial stomach juice of 2 /2 hours.
  • Example 11 grams of N-[6-metl1oxy 2 (methoxymethyl)-4- pyrimidinyl]-sulphamilamide are polymerized with 80 grams of a mixture of 50% of methacrylic acid, 20% of a copolymer from polyvinyl acetate-i-crotonic acid (92:8) and of divinylbenzene, as described in Example 9, at a stirring rate of 150-180 rotations per minute, to form beads.
  • the resulting beads show a half value period for the release of the active substance of 3 /2 hours.
  • Example 12 20 grams of N-[-methoxy 2 (methoxymethyl)-4- pyrimidinyl]-sulphamilamide are polymerised with 80 grams of a mixture of 50% of methacrylic acid, 15% of a copolymer from polyvinyl acetate-l-crotonic acid (92:8) and of divinylbenzene to form beads in the manner described in Example 11.
  • the resulting beads show a half value period for the release of active substance of 11 /2 hours.
  • compositions which contain a predetermined dosage of active medicament, stabilized by being incorporated by bead polymerization in physiologically acceptable synthetic copolymers which are alkali-soluble or at least swollen by the gastro-intestinal juices, said copoymers being selected from the group consisting of copolymers of methacrylic acid and methylmethacrylate, acrylic acid and acrylic acid methyl ester, vinyl acetate and crotonic acid, styrene and acrylic acid, and/or maleic anhydride, vinyl methyl ether and maleic acid anhydride and/or fumaric acid and/ or itaconic acid, wherein control of the size of the beads controls the release of the active medicament in respect of both amount and time and wherein the ratio of active medicament to synthetic copolymer is correlated to the dosage of active medicament, the desired rate of release and regulation of the swelling capacity and alkali solubility of the synthetic copolymer by
  • compositions in bead form as claimed in claim 1 which contain synthetic materials that are insoluble in the gastro-intestinal juices and that are not swollen thereby.
  • compositions in bead form as claimed in claim 1 which contain as synthetic polymers copolymers from mcthacrylic acid and methylmethacrylate.
  • compositions in bead form as claimed in claim 1 which contain as synthetic polymers copolymers from styrene and at least one member of the group selected from acrylic acid, nialeic acid anhydride, fumaric acid, itaconic acid.

Description

United States Patent 3,390,050 STABLE PHARMACEUTICAL BEADS CONTAINING MEDICAMENT INCORPORATED IN SYNTHETIC COPOLYMER BY BEAD POLYMERIZATION Peter Speiser, Forch, Switzerland, assignor to Ciba Corporation, New York, N.Y., a corporation of Delaware No Drawing. Filed June 8, 1965, Ser. No. 462,450 Claims priority, application Switzerland, June 19, 1964, 8,062/ 64 8 Claims. (Cl. 167-83) The present invention relates to pharmaceutical preparations in head form, especially for oral administration, which contain the active ingredient, or mixture of active ingredients, incorporated in physiologically acceptable synthetic polymers, that can be dissolved or swollen by the stomach juice and/or intestinal juice, and to the manufacture of such pharmaceutical preparations.
Hitherto, solid pharmaceutical preparations, for example, for oral administration, were made by aggregating the active ingredient, either alone or in admixture with known adjuvants, for example, starch, sugar, talc, flavouring agents, and the like, and compressing the aggregate into flat circular discs of varying porosity on a tablet compressing machine. Preparations in this form are a further development of the powder which constitutes a single dose. They have many advantages over powders in that they permit more exact dosage, are easier for the patient to take, and permit more accurate selection of the region where resorption is to take place, for example, the mucous membranes of the mouth or of the gastro-intestinal tract. Furthermore, tablets have a longer storage lifebecause they present a small surface area to the hostile environment than powders. A feature which both tablets and powders have in common is that they release the medicament quickly. More recently, attempts have been made to control the release of active ingredients from solid pharmaceutical preparations of the kind defined by means of different methods of manufacture. Such pharmaceutical preparations are known as prolonged release or substained release tablets. The purpose of these tablets is to release the active ingredient, either with or without an initial dose, over a period of several hours, the release being effected either continuously or in portions, the object being to keep the level of active ingredient in the blood as constant as possible. To this end, the medicament is coated with a material which is resistant to the acid secretion of the stomach but which 'is soluble in the secretion of the small intestine, thus preventing quick and premature release in the stomach. The materials first used for such coatings were natural products such as fats and waxes, and these were followed by synthetic adjuvants, which were mainly acrylic and cellulose derivatives. In a further development of the prolonged release form, the medicaments are mixed with syntheic materials of an appropriate grain size which are inert towards and insoluble in the intestinal juice, for example, polyvinyl chloride or polystyrene, and the mixture is compressed into tablets by a known method. The soluble medicament slowly diffuses out of this porous housing. The great drawback to this so-called classical form of prolonged-release tablet is that even very slight and uncontrollable changes in the mode of production result in very great ditferences in the porosity of the preparation or its housing and this, in turn, makes for big differences in the rate at which the active ingredient is released. A process for the manufacture of pharmaceutical preparations having properly controllable release properties has recently been described in which the medicament, or mixture of medicaments, is admixed with synthetic materials and adjuvants and the mixture is proc- "ice essed into tablets free from pores by the known injectionmoulding process.
The pharmaceutical preparations of the invention have substantial technical and pharmacological advantages over the preparations known hitherto. They have a smooth surface which may be transparent or opaque and can be attractively coloured as required. Their manufacture is simple in comparison with other products, especially injection-moulded tablets, since expensive apparatus is not required. They are suitable for both small-scale and large-scale production. Furthermore, the size of the beads can be controlled in a very simple manner, which means that the release of the active ingredient can also be precisely controlled in respect of both amount and time. It has also been found that, in many cases, active ingredients incorporated in such preparations are more stable because the material with which they are coated or in which they are embedded is protective and mechanically stable. They also show a high degree of resistance to atmospheric influence. Since they generally exhibit a low degree of permeability to water, the preparations made by the process of the invention are special-1y suitable for hygroscopic medicaments and/ or medicaments that are sensitive to moisture.
The preparations made by the process of the invention may be used per se, for example, in the form of granules, if desired, in capsules, or suspended in a liquid, for example, as a suspension or in the form of a syrup. However, the product may also be admixed with adjuvants, and compressed into tablets in the customary manner.
The synthetic materials used are those whose monomers can be subjected to bead polymerization in the presence of the active ingredients and which, when cured, yield a physiologically acceptable polymer of adequate strength that can be at least swollen, e.g. dissolved by the gastrointestinal juices. Synthetic materials of the kind defined are advantageously copolymers of methacrylic acid and methylmethacrylate, acrylic acid and acrylic acid methyl ester, vinyl acetate and crotonic acid, styrene and acrylic acid, and/or maleic anhydride, vinyl methyl ether and maleic acid anhydride and/or fumaric acid and/or itaconic acid, and the swelling capacity and alkali-solubility of the synthetic material can be regulated by changing the proportion of free acid present in the copolymer.
The ratio of active ingredient to synthetic material in the preparations of the invention depends on the dosage of active ingredient and the desired rate of release.
The new preparations may also contain fillers or swelling agents, for example, parafiins, starch derivatives, talc, stearates, and also electrolytes. Furthermore, interfaceactive substances such as fatty alcohols or fatty acids may be added to render lipophilic substances hydrophilic, and substances which render hydrophilic substances lipophilic, such as alkylamines, for example, hexadecylamine, or organic silicones, for example, dirnethyldichlorosilane. They may also contain the medicament, or mixture of medicaments, or parts thereof, enveloped in wax or fat, and also synthetic resins that are insoluble in the stomach juice and/or intestinal juice and that are not swollen thereby, and thus constitute a prolonged release preparation.
The new pharmaceutical preparations of the invention are obtained when a medicament, or a mixture of medicaments, if desired or required, together with fillers and swelling agents and/or further adjuvants, is subjected to bead polymerization in admixture with monomers which yield physiologically acceptable synthetic materials which are dissolved or swollen by the stomach juice and/ or intestinal juice when polymerized. In the said process, the medicament or mixture of medicaments, may be dissolved or suspended in the monomers, the adjuvants added, and
the mixture thus obtained dispersed, for example, by stirring, in a dispersing agent with which it is immiscible, for example, water, in such a manner that beads having the requisite degree of fineness are obtained. Polymerization may even be carried out at room temperature if the appropriate monomers are used, although it is normally carried out at an elevated temperature. The beads that are formed are separated from the dispersing agent, washed, and dried.
The catalyst used is one of those normally employed for this reaction, for example, an inorganic or organic peroxide, for example, benzoyl peroxide and tertiarybutyl hydroperoxide or an azonitrile, for example, Ot-aZO- diiso-outyronitrile. An organic tertiary-amine, an iron salt, manganese, cobalt, a sulphinic acid or a sulphite can be added to accelerate polymerization.
The following examples illustrate the invention.
Example 1 10 grams of -(l-cyclohexenyl)-5-ethyl-calcium barbiturate and 32 grams of a vinyl acetate-crotonic acid copolymer (92:8) are dissolved in a mixture of 40 grams of methacrylic acid monomer and 25 grams of methylmethacrylate monomer. The viscous solution is emulsified in 200 millilitres of a solution of 0.4 gram of sodium polyacrylate and 20 grams of sodium sulphate in 100 millilitres of water in a vessel provided with stirring means, a reflux condenser and a tube for the introduction of gas; 0.5 millilitre of benzoyl peroxide is added, and the batch is polymerized at about 60 C. at a stirring speed of 200 r.p.m. and with the introduction of CO Polymerization is finished after about 2 hours, and the product consists of dull white beads between 0.1 and 3.0 millimetres in diameter and having a smooth surface. The beads are washed with distilled water and, if desired, dried at 40 C.
Example 2 grams of acctyl-para-phenetidine and 30 grams of a copolymer from acrylic acid ethyl ester, tertiary butylacrylamide and acrylic acid are dissolved or suspended in a mixture comprising 40 grams of methacrylic acid monomer and 27 grams of methylmethacrylate monomer. The suspension is further treated and polymerized in a manner analogous to that described in Example 1, but at a temperature of 50 C. and a stirring speed of 500 r.p.m. Polymerization is finished after about 2 hours, the product comprising yellowish white beads having a mean diameter of 0.2 to 0.3 millimetre.
Example 3 100 grams of 2-etl1yl-2-phenyl-glutarimide are dissolved in a solution of 30 grams of a vinyl acetate-crotonic acid copolymer (92:8) in 40 grams of methacrylic acid monomer and 30 grams of methyl-methacrylate monomer. The
solution is emulsified in 550 millilitres of a solution of 0.4
gram of sodium polyacrylate and grams of sodium sulphate in 100 millilitres of water in a manner analogous to that described in Example 1. 0.5 gram of oc-HZO-iSO- butyronitrile is added, and the batch is polymerized for 3 hours at a temperature of 60 C., while stirring at 500 r.p.m. White beads having a means diameter of 0.4 to 0.6 millimetre are obtained.
Example 4 grams of papaverine base and 20 grams of a vinyl acetate-crotonic acid copolymer (92:8) are dissolved in 43 grams of methyl-methacrylate monomer. The solution is emulsified in 275 millilitres of a solution of 0.4 gram of sodium polyacrylate and 20 grams of sodium sulphate in 100 millilitres of water in a manner analogous to that described in Example 1. 0.3 millilitre of benzoyl peroxide is added, and the batch is polymerized at 50 C. at a stirring speed of 200 r.p.m. After 1 hour, greenish brown beads having a mean diameter of l to 3 millimetres are obtained.
Example 5 15 grams of arachis oil, 15 grams of a copolymer from acrylic acid ethyl ester, tertiary butylacrylamide and acrylic acid and 20 grams of 4-dimethylamino-l-phenyl-Z:3- dimethylpyrazolone-S are trituratcd With grams of methylmethacrylate, and then further treated and polymerized in a manner analogous to that described in Example 1, but at a stirring speed of 500 r.p.m. Yellowish white beads having a mean diameter of 0.2 to 0.4 millimetre are obtained.
Example 6 10 grams of hydrocortisone are suspended in 90 grams of a mixture comprising 3 grams of methylmethacrylate, 3 grams of polyvinyl acetate-crotonic acid copolymer (92:8) and 4 grams of methacrylic acid. 0.5 millilitre of benzoyl peroxide is added and the suspension is emulsified in 250 millilitres of a solution comprising 0.4 gram of sodium polyacrylate and 20 grams of sodium sulphate per 100 millilitres of water. The batch is then polymerized for 3 hours at C. while stirring at 250 r.p.m. and with the introduction of CO White beads having a mean diameter of 0.7 to 2.0 millimetres are obtained.
Example 7 25 grams of N-[6-methoxy 2 (methoxymethyl)-4- pyrimidinyl]-sulphanilimide are dissolved at C. in grams of a mixture comprising 3 grams of polyvinyl acetate-crotonic acid copolymer (92:8), 3 grams of methylmethacrylate and 4 grams of methacrylic acid. 0.07 gram of a-azoisobutyronitrile is added and the mixture is then emulisfied in 250 millilitres of a solution of 0.4 gram of sodium polyacrylate and 20 grams of sodium sulphate in 100 millilitres of water. The batch is polymerized for 2 hours at 70 C. while stirring at 300 r.p.m. and with the introduction of CO Yellow translucent beads having a mean diameter of 0.5 to 1.0 millimetre are obtained.
Example 8 15 grams of 3-acetylamino-2z4:6-tri-i0dobenz0ic acid (Acetrizons DCI) in the form of the sodium salt are dissolved at 70 C. in grams of a mixture comprising 3 grams of methylmethacrylate, 3 grams of polyvinyl acetate-crotonic acid copolymer (92:8) and 4 grams of methacrylic acid. 0.2 gram of benzoyl peroxide is added and the mixture is then emulsified in 250 millilitres of a solution of 0.3 gram of high-molecular polyethylene glycol and 10 grams of sodium suphate in millilitres of dilute hydrochloric acid (0.01 N). The batch is polymerized for 3 hours at 70 C. while stirring at 250 r.p.m. and with the introduction of CO White beads having a mean diameter of 0.5 to 1.0 millimetre are obtained.
Example 9 20 grams of N [6-methoxy 2 (methoxymethyl)-4- pyrimidinyl]-sulphamilamide are dissolved at 70 C. in 80 grams of a mixture comprising 10% of methacrylic acid, 40% of methyl methacrylate, 30% of polyvinyl acetate crotonic acid coploymer (92:8) and 20% of divinylbenzene. After dispersion in 300 ml. of a saturated aqueous solution of sodium sulfate with 0.4% of polyacrylate having a pH value of 6, the batch is copolymerised with the addition of 0.2 gram of azoisobutyronitrile at 70 C. for 5 hours at a stirring rate of 300 rotations per minute.
The resulting beads show a half value period for the release of active substance of one hour in artificial intestinal juice having a pH value of 7.5 at 37 C.
Example 10 20 grams of N-[6-methoxy 2 (methoxymethyl)-4- pyrimidinyl]-sulphamilamide are processed with 80 grams of a mixture of 50% of methacrylic acid, 30% ot a copolymer of polyvinyl acetate-l-crotonic acid (92:8) and 20% of divinylbcnzene under the same conditions as described in Example 9 to form beads.
The resulting beads show a half value period for the release in artificial stomach juice of 2 /2 hours.
Example 11 grams of N-[6-metl1oxy 2 (methoxymethyl)-4- pyrimidinyl]-sulphamilamide are polymerized with 80 grams of a mixture of 50% of methacrylic acid, 20% of a copolymer from polyvinyl acetate-i-crotonic acid (92:8) and of divinylbenzene, as described in Example 9, at a stirring rate of 150-180 rotations per minute, to form beads.
The resulting beads show a half value period for the release of the active substance of 3 /2 hours.
Example 12 20 grams of N-[-methoxy 2 (methoxymethyl)-4- pyrimidinyl]-sulphamilamide are polymerised with 80 grams of a mixture of 50% of methacrylic acid, 15% of a copolymer from polyvinyl acetate-l-crotonic acid (92:8) and of divinylbenzene to form beads in the manner described in Example 11.
The resulting beads show a half value period for the release of active substance of 11 /2 hours.
What is claimed is:
1. Pharmaceutical oral, controlled-size, bead dosageform preparations, 0.1 to 3.0 mm. in diameter, which contain a predetermined dosage of active medicament, stabilized by being incorporated by bead polymerization in physiologically acceptable synthetic copolymers which are alkali-soluble or at least swollen by the gastro-intestinal juices, said copoymers being selected from the group consisting of copolymers of methacrylic acid and methylmethacrylate, acrylic acid and acrylic acid methyl ester, vinyl acetate and crotonic acid, styrene and acrylic acid, and/or maleic anhydride, vinyl methyl ether and maleic acid anhydride and/or fumaric acid and/ or itaconic acid, wherein control of the size of the beads controls the release of the active medicament in respect of both amount and time and wherein the ratio of active medicament to synthetic copolymer is correlated to the dosage of active medicament, the desired rate of release and regulation of the swelling capacity and alkali solubility of the synthetic copolymer by changing the proportion of free acid present in the copolymer.
2. Pharmaceutical preparations in bead form as claimed in claim 1, which contain at least parts of the medicaments enveloped in waxes or fats.
3. Pharmaceutical preparations in bead form as claimed in claim 1, which contain fillers, swelling agents and/ or interface-active substances.
4. Pharmaceutical preparations in bead form as claimed in claim 1, which contain synthetic materials that are insoluble in the gastro-intestinal juices and that are not swollen thereby.
5. Pharmaceutical preparations in bead form as claimed in claim 1, which contain as synthetic polymers copolymers from mcthacrylic acid and methylmethacrylate.
6. Pharmaceutical preparations in bead form as claimed in claim 1, which contain as synthetic polymers copolymers from acrylic acid and acrylic acid methyl ester.
7. Pharmaceutical preparations in bead form as claimed in claim 1, which contain as synthetic polymers copolymers from vinyl acetate and crotonic acid.
8. Pharmaceutical preparations in bead form as claimed in claim 1, which contain as synthetic polymers copolymers from styrene and at least one member of the group selected from acrylic acid, nialeic acid anhydride, fumaric acid, itaconic acid.
References Cited UNITED STATES PATENTS 2,810,716 10/1957 Markus 260-881 2,846,057 8/1958 Polin 206-.5 3,074,795 1/1963 Friedman et al. 992 3,092,553 6/1963 Fisher et al. 167-82 3,121,043 2/1964 Tobin et al. 167-82 3,158,538 11/1964 Lee 167-55 3,162,573 12/1964 Geary 167-53 3,202,577 8/1965 Markus 167-55 3,247,066 4/1966 Milosovich 167-82 3,328,256 6/1967 Gaunt 167-82 LEWIS GOTTS, Primary Examiner.
S. K. ROSE, Assistant Examiner.

Claims (1)

1. PHARMACEUTICAL ORAL, CONTROLLED-SIZE, BEAD DOSAGEFORM PREPARATION, 0.1 TO 3.0 MM. IN DIAMETER, WHICH CONTAIN A PREDETERMINED DOSAGE OF ACTIVE MEDICAMENT, STABILIZED BY BEING INCORPORATED BY BEAD POLYMERIZATION IN PHYSIOLOGICALLY ACCEPTABLE SYNTHETIC COPOLYMERS WHICH ARE ALKALI-SOLUBLE OR AT LEAST SWOLLEN BY THE GASTRO-INTESTINAL JUICES, SAID COPOYMERS BEING SELECTED FROM THE GROUP CONSISTING OF COPOLYMERS OF METHACRYLIC ACID AND METHYLMETHACRYLATE, ACRYLIC ACID AND ACRYLIC ACID METHYL ESTER, VINYL ACETATE AND CROTONIC ACID, STYRENE AND ACRYLIC ACID, AND/OR MALEIC ANHYDRIDE, VINYL METHYL ETHER AND MALEIC ACID ANHYDRIDE AND/OR FUMARIC ACID AND/OR ITACONIC ACID, WHEREIN CONTROL OF THE SIZE OF THE BEADS CONTROLS THE RELEASE OF THE ACTIVE MEDICAMENT IN RESPECT OF BOTH AMOUNT AND TIME AND WHEREIN THE RATIO OF ACTIVE MEDICAMENT TO SYNTHETIC COPOLYMER IS CORRELATED TO THE DOSAE OF ACTIVE MEDICAMENT, THE DESIRED RATE OF RELEASE AND REGULATION OF THE SWELLING CAPACITY AND ALKALI SOLUBILITY OF THE SYNTHETIC COPOLYMER BY CHANGING THE PROPORTION OF FREE ACID PRESENT IN THE COPOLYMER.
US462450A 1964-06-19 1965-06-08 Stable pharmaceutical beads conaining medicament incorporated in synthetic copolymerby bead polymerization Expired - Lifetime US3390050A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH806264A CH468192A (en) 1964-06-19 1964-06-19 Process for the manufacture of medicaments in pearl form
CH705065 1965-05-20

Publications (1)

Publication Number Publication Date
US3390050A true US3390050A (en) 1968-06-25

Family

ID=25700654

Family Applications (1)

Application Number Title Priority Date Filing Date
US462450A Expired - Lifetime US3390050A (en) 1964-06-19 1965-06-08 Stable pharmaceutical beads conaining medicament incorporated in synthetic copolymerby bead polymerization

Country Status (6)

Country Link
US (1) US3390050A (en)
BE (1) BE665607A (en)
CH (1) CH468192A (en)
DE (1) DE1467843A1 (en)
FR (1) FR1468716A (en)
GB (1) GB1116670A (en)

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE28316E (en) * 1968-09-03 1975-01-21 Entrapment compositions and processes
US4539199A (en) * 1981-01-14 1985-09-03 Egyt Gyogyszervegyeszeti Gyar Sustained release pharmaceutical compositions
US4547359A (en) * 1983-04-18 1985-10-15 Boehringer Ingelheim Kg Divisible pharmaceutical tablet with delayed active ingredient release
US4548990A (en) * 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US4555398A (en) * 1982-10-05 1985-11-26 Chisso Corporation Sustained-release vasodilator
US4624848A (en) * 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4642233A (en) * 1982-03-22 1987-02-10 Alza Corporation Gastrointestinal drug delivery system comprising a hydrogel reservoir containing a plurality of tiny pills
US4649043A (en) * 1982-03-22 1987-03-10 Alza Corporation Drug delivery system for delivering a plurality of tiny pills in the gastrointestinal tract
US4659558A (en) * 1982-03-22 1987-04-21 Alza Corporation Oral delivery system comprising a plurality of tiny pills for delivering drug in the stomach and intestine
US4690825A (en) * 1985-10-04 1987-09-01 Advanced Polymer Systems, Inc. Method for delivering an active ingredient by controlled time release utilizing a novel delivery vehicle which can be prepared by a process utilizing the active ingredient as a porogen
US4749576A (en) * 1984-05-10 1988-06-07 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4764380A (en) * 1982-03-22 1988-08-16 Alza Corporation Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills
US4795436A (en) * 1983-11-14 1989-01-03 Bio-Mimetics, Inc. Bioadhesive composition and method of treatment therewith
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US4853229A (en) * 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
US4882166A (en) * 1981-09-30 1989-11-21 National Research Development Corporation Compositions comprising encapsulated particles and their preparation
US4940556A (en) * 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
WO1990007882A1 (en) * 1989-01-19 1990-07-26 Wm. Wrigley Jr. Company Gum composition containing dispersed porous beads containing active chewing gum ingredients and method
US4961932A (en) * 1987-10-26 1990-10-09 Alza Corporation Plurality of tiny pills in liquid dosage form
US4983392A (en) * 1983-11-14 1991-01-08 Bio-Mimetics, Inc. Bioadhesive compositions and methods of treatment therewith
US5023080A (en) * 1988-06-17 1991-06-11 Basic Bio Systems, Inc. Time release protein
EP0431719A1 (en) 1989-10-31 1991-06-12 Columbia Laboratories, Inc. Vaginal tissue moisturizing composition
US5030454A (en) * 1987-10-26 1991-07-09 Alza Corporation Method for delivering drug in tiny pills in liquid carrier
US5055300A (en) * 1988-06-17 1991-10-08 Basic Bio Systems, Inc. Time release protein
WO1991015105A2 (en) * 1990-12-20 1991-10-17 Wm. Wrigley Jr. Company Gum composition having dispersed porous beads containing plasticizers
US5064698A (en) * 1989-02-16 1991-11-12 Wm. Wrigley, Jr. Company Food packaging improvements
US5079005A (en) * 1988-06-17 1992-01-07 Gupta Kashmiri L Time release protein
DE4029591A1 (en) * 1990-09-19 1992-03-26 Stockhausen Chem Fab Gmbh METHOD FOR PRODUCING POLYMER-BASED ABSORPTION MATERIAL WITH THE ADDITION OF WATER-SOLUBLE SUBSTANCES AND USE OF THIS ABSORPTION MATERIAL FOR ACQUIRING AND / OR SUBSEQUENTLY DELIVERING WATER OR AQUEOUS SOLUTIONS
US5126174A (en) * 1989-02-16 1992-06-30 Wm. Wrigley Jr. Company Food packaging improvements
US5139787A (en) * 1989-01-19 1992-08-18 Wm. Wrigley Jr. Company Gum composition containing dispersed porous beads containing active chewing gum ingredients and method
US5154927A (en) * 1989-01-19 1992-10-13 Wm. Wrigley Jr. Company Gum composition containing dispersed porous beads containing active chewing gum ingredients and method
US5198226A (en) * 1986-01-30 1993-03-30 Syntex (U.S.A.) Inc. Long acting nicardipine hydrochloride formulation
US5246714A (en) * 1985-10-11 1993-09-21 Aktiebolaget Hassle Drug preparation

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA935092A (en) * 1968-09-03 1973-10-09 S. Banker Gilbert Molecular drug entrapment process and compositions
CA927282A (en) * 1968-09-03 1973-05-29 S. Banker Gilbert Entrapment compositions and processes
DE2037947C3 (en) * 1969-08-01 1983-01-13 Bush Boake Allen Ltd., London Encapsulated preparations
FR2407720A1 (en) * 1977-11-08 1979-06-01 Lipha Lyonnaise Indle Pharmace Oral sustained-action capsule formulations - of drug and excipient which swells in contact with digestive juices
ES259491Y (en) * 1981-07-15 1982-07-01 GARDENING
GB8331546D0 (en) * 1983-11-25 1984-01-04 Exxon Research Engineering Co Polymeric compositions
EP0143608B1 (en) * 1983-11-25 1992-07-22 Ciba Specialty Chemicals Water Treatments Limited Manufacture and use of polymeric beads
DE3524337A1 (en) * 1985-07-08 1987-01-08 Roehm Gmbh MEDICINAL PACKAGING
DE3608721A1 (en) * 1986-03-15 1987-09-17 Hoelter Heinz Method for improving the service life of chemisorption compositions
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2810716A (en) * 1954-06-28 1957-10-22 White Lab Inc Batchwise copolymerization technique
US2846057A (en) * 1954-02-09 1958-08-05 Polin Herbert Spencer Devices for dosage control
US3074795A (en) * 1959-11-12 1963-01-22 Pfizer & Co C Production of bacitracin adsorbate and process of administration to animals for promoting growth
US3092553A (en) * 1959-01-30 1963-06-04 Jr Carl E Fisher Pharmaceutical preparations and method and apparatus for making same
US3121043A (en) * 1960-05-11 1964-02-11 Scient Associates Inc Sustained release pharmaceutical preparation and methods for making same
US3158538A (en) * 1961-02-23 1964-11-24 White Lab Inc Antidiarrheal compositions and method of using
US3162573A (en) * 1959-10-14 1964-12-22 Plants Products Corp Internal treatment of animals with resin biocidal compositions
US3202577A (en) * 1962-05-25 1965-08-24 White Lab Inc Process of treating diarrhea with resins
US3247066A (en) * 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
US3328256A (en) * 1963-05-27 1967-06-27 William E Gaunt Spherical beads and their production

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2846057A (en) * 1954-02-09 1958-08-05 Polin Herbert Spencer Devices for dosage control
US2810716A (en) * 1954-06-28 1957-10-22 White Lab Inc Batchwise copolymerization technique
US3092553A (en) * 1959-01-30 1963-06-04 Jr Carl E Fisher Pharmaceutical preparations and method and apparatus for making same
US3162573A (en) * 1959-10-14 1964-12-22 Plants Products Corp Internal treatment of animals with resin biocidal compositions
US3074795A (en) * 1959-11-12 1963-01-22 Pfizer & Co C Production of bacitracin adsorbate and process of administration to animals for promoting growth
US3121043A (en) * 1960-05-11 1964-02-11 Scient Associates Inc Sustained release pharmaceutical preparation and methods for making same
US3158538A (en) * 1961-02-23 1964-11-24 White Lab Inc Antidiarrheal compositions and method of using
US3202577A (en) * 1962-05-25 1965-08-24 White Lab Inc Process of treating diarrhea with resins
US3247066A (en) * 1962-09-12 1966-04-19 Parke Davis & Co Controlled release dosage form containing water-swellable beadlet
US3328256A (en) * 1963-05-27 1967-06-27 William E Gaunt Spherical beads and their production

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE28316E (en) * 1968-09-03 1975-01-21 Entrapment compositions and processes
US4539199A (en) * 1981-01-14 1985-09-03 Egyt Gyogyszervegyeszeti Gyar Sustained release pharmaceutical compositions
US4882166A (en) * 1981-09-30 1989-11-21 National Research Development Corporation Compositions comprising encapsulated particles and their preparation
US4764380A (en) * 1982-03-22 1988-08-16 Alza Corporation Drug delivery system comprising a volume increasing matrix containing a plurality of tiny pills
US4642233A (en) * 1982-03-22 1987-02-10 Alza Corporation Gastrointestinal drug delivery system comprising a hydrogel reservoir containing a plurality of tiny pills
US4649043A (en) * 1982-03-22 1987-03-10 Alza Corporation Drug delivery system for delivering a plurality of tiny pills in the gastrointestinal tract
US4659558A (en) * 1982-03-22 1987-04-21 Alza Corporation Oral delivery system comprising a plurality of tiny pills for delivering drug in the stomach and intestine
US4555398A (en) * 1982-10-05 1985-11-26 Chisso Corporation Sustained-release vasodilator
US4595587A (en) * 1983-04-18 1986-06-17 Boehringer Ingelheim Kg Divisible pharmaceutical tablet with delayed active ingredient release
US4547359A (en) * 1983-04-18 1985-10-15 Boehringer Ingelheim Kg Divisible pharmaceutical tablet with delayed active ingredient release
US4548990A (en) * 1983-08-15 1985-10-22 Ciba-Geigy Corporation Crosslinked, porous polymers for controlled drug delivery
US4795436A (en) * 1983-11-14 1989-01-03 Bio-Mimetics, Inc. Bioadhesive composition and method of treatment therewith
US4983392A (en) * 1983-11-14 1991-01-08 Bio-Mimetics, Inc. Bioadhesive compositions and methods of treatment therewith
US4749576A (en) * 1984-05-10 1988-06-07 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4624848A (en) * 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4690825A (en) * 1985-10-04 1987-09-01 Advanced Polymer Systems, Inc. Method for delivering an active ingredient by controlled time release utilizing a novel delivery vehicle which can be prepared by a process utilizing the active ingredient as a porogen
US5246714A (en) * 1985-10-11 1993-09-21 Aktiebolaget Hassle Drug preparation
US5198226A (en) * 1986-01-30 1993-03-30 Syntex (U.S.A.) Inc. Long acting nicardipine hydrochloride formulation
US4940556A (en) * 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
US4851232A (en) * 1987-02-13 1989-07-25 Alza Corporation Drug delivery system with means for obtaining desirable in vivo release rate pattern
US4961932A (en) * 1987-10-26 1990-10-09 Alza Corporation Plurality of tiny pills in liquid dosage form
US4853229A (en) * 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
US5030454A (en) * 1987-10-26 1991-07-09 Alza Corporation Method for delivering drug in tiny pills in liquid carrier
US5023080A (en) * 1988-06-17 1991-06-11 Basic Bio Systems, Inc. Time release protein
US5079005A (en) * 1988-06-17 1992-01-07 Gupta Kashmiri L Time release protein
US5055300A (en) * 1988-06-17 1991-10-08 Basic Bio Systems, Inc. Time release protein
WO1990007882A1 (en) * 1989-01-19 1990-07-26 Wm. Wrigley Jr. Company Gum composition containing dispersed porous beads containing active chewing gum ingredients and method
US5139787A (en) * 1989-01-19 1992-08-18 Wm. Wrigley Jr. Company Gum composition containing dispersed porous beads containing active chewing gum ingredients and method
US5154927A (en) * 1989-01-19 1992-10-13 Wm. Wrigley Jr. Company Gum composition containing dispersed porous beads containing active chewing gum ingredients and method
US4963369A (en) * 1989-01-19 1990-10-16 Wm. Wrigley Jr. Co. Gum composition containing dispersed porous beads containing active chewing gum ingredients and method
US5064698A (en) * 1989-02-16 1991-11-12 Wm. Wrigley, Jr. Company Food packaging improvements
US5126174A (en) * 1989-02-16 1992-06-30 Wm. Wrigley Jr. Company Food packaging improvements
EP0431719A1 (en) 1989-10-31 1991-06-12 Columbia Laboratories, Inc. Vaginal tissue moisturizing composition
DE4029591A1 (en) * 1990-09-19 1992-03-26 Stockhausen Chem Fab Gmbh METHOD FOR PRODUCING POLYMER-BASED ABSORPTION MATERIAL WITH THE ADDITION OF WATER-SOLUBLE SUBSTANCES AND USE OF THIS ABSORPTION MATERIAL FOR ACQUIRING AND / OR SUBSEQUENTLY DELIVERING WATER OR AQUEOUS SOLUTIONS
WO1991015105A3 (en) * 1990-12-20 1991-11-28 Wrigley W M Jun Co Gum composition having dispersed porous beads containing plasticizers
WO1991015105A2 (en) * 1990-12-20 1991-10-17 Wm. Wrigley Jr. Company Gum composition having dispersed porous beads containing plasticizers
US5154938A (en) * 1990-12-20 1992-10-13 Wm. Wrigley Jr. Company Gum composition having dispersed porous beads containing plasticizers

Also Published As

Publication number Publication date
BE665607A (en) 1965-12-20
CH468192A (en) 1969-02-15
FR1468716A (en) 1967-02-10
DE1467843A1 (en) 1968-12-12
GB1116670A (en) 1968-06-12

Similar Documents

Publication Publication Date Title
US3390050A (en) Stable pharmaceutical beads conaining medicament incorporated in synthetic copolymerby bead polymerization
US3432592A (en) Injection-moulded oral medicament in solid form
JP4944334B2 (en) Dispersion with nonionic emulsifier
US4814179A (en) Floating sustained release therapeutic compositions
EP0277127B1 (en) New drug preparation with controlled release of the active compound, and a method for the manufacture thereof
CA2839689C (en) Coating composition suitable for pharmaceutical or nutraceutical dosage forms
JP4653399B2 (en) Pharmaceutical dosage form and method for producing the same
KR100510356B1 (en) Pharmaceutical formulations comprising a coating and binding agent with improved storage stability and process for the preparation thereof
KR880002673B1 (en) Analgesic capsule
CA2839494C (en) Coating composition suitable for pharmaceutical or nutraceutical dosage forms
PT85819B (en) METHOD FOR PREPARING COATING MEMBRANES AND PHARMACEUTICAL COMPOSITIONS OBTAINED FROM THEM
KR20040065989A (en) New Film Coating
US4925675A (en) Erythromycin microencapsulated granules
US4155993A (en) Prolonged-release pharmaceutical compositions for oral administration, their methods of making and use
JPH0830004B2 (en) Bioadhesive composition and method of treatment therewith
IE55190B1 (en) Extended action controlled release compositions
KR20010079560A (en) Coating and excipient agent for oral or dermal dosage forms
WO1991006281A1 (en) Gastric preparation
KR20050034620A (en) Granulate or powder for producing coating or binding agents for medicaments
US3328256A (en) Spherical beads and their production
JPH10502056A (en) Modifiable starch acetate compositions and methods of making and using the same
Alhalmi et al. Sustained release matrix system: an overview
KR100429694B1 (en) Slow release of valproate metal salt
ZA200006440B (en) Oral medicinal preparations with reproducible release of the active ingredient gatifloxacin or its pharmaceutically suitable salts or hydrates.
IE46594B1 (en) Copolymers of methyl methacrylate and nitrogen-containing acrylate or methacrylate esters